Reporting Hub https://www.jnj.com/janssen-announces-48-week-results-of-phase-3b-study-demonstrating-the-safety-and-efficacy-of-long-acting-injectable-hiv-treatment-of-rilpivirine-and-cabotegravir-administered-every-two-months https://www.jnj.com/janssen-announces-results-of-phase-3-study-demonstrating-the-safety-and-efficacy-of-long-acting-injectable-hiv-treatment-regimen-of-rilpivirine-and-cabotegravir-through-96-weeks https://www.mosaicostudy.com/ https://imbokodo.org.za/about https://www.jnj.com/janssen-announces-health-canada-approval-of-cabenuva-the-first-long-acting-regimen-for-the-treatment-of-hiv https://www.janssen.com/emea/sites/www_janssen_com_emea/files/janssen_announces_european_commission_authorisation_of_the_first_complete_long-acting_injectable_hiv_treatment_in_europe.pdf https://www.janssen.com/janssen-announces-us-fda-approval-cabenuva-rilpivirine-and-cabotegravir-first-long-acting-regimen https://www.jnj.com/janssen-announces-health-canada-approval-of-cabenuva-the-first-long-acting-regimen-for-the-treatment-of-hiv HIV prevention for women: The first long-acting HIV prevention method specifically designed for women, the monthly dapivirine ring, developed by the International Partnership for Microbicides using exclusive rights to our ARV compound, received a positive opinion from EMA as part of its EU-M4all program.